Jun Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jun Zhao has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Xiaoling Zhang
The Affiliated Hospital of Changzhi Medical College
11 shared publicationsYunyi Du
Changzhi People’s Hospital Affiliated to Changzhi Medical College
11 shared publicationsWenqing Hu
Changzhi People’s Hospital Affiliated to Changzhi Medical College
10 shared publicationsFei Su
The Affiliated Hospital of Changzhi Medical College
9 shared publicationsWeiling Li
Department of Oncology, The People's Hospital of Jianyang City, Jianyang, Sichuan, 641400, China
6 shared publicationsYangjun Gao
The Affiliated Hospital of Changzhi Medical College
6 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1)
Efficacy and safety of radiofrequency hyperthermia combined with immune checkpoint inhibitors and chemotherapy as first-line treatment for HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma: A propensity score–matched study
Gastric cancer is one of the most common malignancies worldwide and imposes a substantial disease burden.1 In China, it ranks fifth in incidence and third in mortality.2 In recent years, the incide...
- 28 September 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1)
Open AccessEfficacy and safety of radiofrequency hyperthermia combined with immune checkpoint inhibitors and chemotherapy as first-line treatment for HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma: A propensity score–matched study
Gastric cancer is one of the most common malignancies worldwide and imposes a substantial disease burden.1 In China, it ranks fifth in incidence and third in mortality.2 In recent years, the incide...
- Open Access
- 1 September 2026
- Published by SAGE Publications in Cancer Control
- Vol. 33
Assessment of Immunotherapy Response by Analyzing Tumor Microenvironment Alterations in Advanced Gastric Cancer: A Study Protocol
Introduction: Advanced gastric cancer has a poor prognosis, and reliable biomarkers for identifying patients who may benefit from immune checkpoint inhibitors (ICIs) combined with chemotherapy remain limited. Dynamic alterations in the tumor microenvironment (TME) may provide clinically useful information regarding treatment response. This study aims to investigate longitudinal TME changes in patients with advanced gastric cancer receiving ICIs plus chemotherapy and to explore their associations with treatment response. Methods: This is a prospective, single-center biomarker study in patients with advanced gastric cancer receiving ICIs plus chemotherapy. Matched tumor tissue samples from primary and/or metastatic lesions, together with peripheral blood samples, will be collected before treatment and after four cycles of combination therapy. Patients achieving complete response (CR) or partial response (PR) will be classified as the high-response group (HRG), whereas patients with progressive disease (PD) will be classified as the non-response group (NRG). Pre- and post-treatment TME alterations will be analyzed within each patient, and differences between the HRG and NRG will be compared, including tumor-infiltrating lymphocytes (TILs), H3K4me3, cytokines, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and tumor markers. Associations with programmed death-ligand 1 (PD-L1), mismatch repair (MMR), and Epstein–Barr virus-encoded RNA (EBER) status will also be explored. Conclusions: This study may identify dynamic TME-related biomarkers associated with response to ICIs combined with chemotherapy, and may provide evidence for future response-stratification strategies in advanced gastric cancer.
- 1 September 2026
- Published by SAGE Publications in Cancer Control
- Vol. 33
Open AccessAssessment of Immunotherapy Response by Analyzing Tumor Microenvironment Alterations in Advanced Gastric Cancer: A Study Protocol
Introduction: Advanced gastric cancer has a poor prognosis, and reliable biomarkers for identifying patients who may benefit from immune checkpoint inhibitors (ICIs) combined with chemotherapy remain limited. Dynamic alterations in the tumor microenvironment (TME) may provide clinically useful information regarding treatment response. This study aims to investigate longitudinal TME changes in patients with advanced gastric cancer receiving ICIs plus chemotherapy and to explore their associations with treatment response. Methods: This is a prospective, single-center biomarker study in patients with advanced gastric cancer receiving ICIs plus chemotherapy. Matched tumor tissue samples from primary and/or metastatic lesions, together with peripheral blood samples, will be collected before treatment and after four cycles of combination therapy. Patients achieving complete response (CR) or partial response (PR) will be classified as the high-response group (HRG), whereas patients with progressive disease (PD) will be classified as the non-response group (NRG). Pre- and post-treatment TME alterations will be analyzed within each patient, and differences between the HRG and NRG will be compared, including tumor-infiltrating lymphocytes (TILs), H3K4me3, cytokines, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and tumor markers. Associations with programmed death-ligand 1 (PD-L1), mismatch repair (MMR), and Epstein–Barr virus-encoded RNA (EBER) status will also be explored. Conclusions: This study may identify dynamic TME-related biomarkers associated with response to ICIs combined with chemotherapy, and may provide evidence for future response-stratification strategies in advanced gastric cancer.
- 27 April 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 223, 105347
Emerging treatment paradigms for gastric cancer peritoneal metastasis in the era of multimodal precision therapy
- 27 April 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 223, 105347
Emerging treatment paradigms for gastric cancer peritoneal metastasis in the era of multimodal precision therapy
- 24 April 2026
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 27 (1) , 23
Advances in Pharmacologic- and Non-pharmacologic Interventions for Cancer Pain: A Narrative Review
- 24 April 2026
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 27 (1) , 23
Advances in Pharmacologic- and Non-pharmacologic Interventions for Cancer Pain: A Narrative Review
- Open Access
- 14 April 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1764358
Safety and efficacy of PEG-rhG-CSF as primary prophylaxis for neutropenia in gastrointestinal cancer patients receiving combination chemotherapy including oral agents: a prospective, exploratory, non-randomized controlled study
Purpose: The safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for prevention of chemotherapy-induced neutropenia (CIN) in patients undergoing oral chemotherapy remain unclear. This study aimed to investigate the safety and efficacy of PEG-rhG-CSF as primary prophylaxis for CIN in gastrointestinal (GI) cancer patients receiving combination chemotherapy regimens that include oral chemotherapy agents. Methods: This is a prospective, single-center, open-label, exploratory, non-randomized controlled study. GI cancer patients was treated with intravenous oxaliplatin (130mg/m 2 on day 1) combined with either oral capecitabine (1000mg/m 2 ) or S−1 (an oral fluoropyrimidine combination of tegafur, gimeracil, and oteracil potassium; 40–60 mg) administered twice daily on days 1–14 of a 3−week cycle. The treatment group received subcutaneous injection of PEG-rhG-CSF (6mg) 24 hours after oxaliplatin, while the control group received no primary prophylaxis. The primary endpoint was safety, and secondary endpoints included the incidence of CIN. Results: Between March 2022 and January 2023, 49 patients were screened, and 43 patients who completed at least two treatment cycles were included in the final analysis (26 in treatment group and 17 in control group). The overall adverse events (AEs) did not differ statistically (93.8% vs 100.0%, p = 0.542). For grade ≥ 3 AEs, the incidence of neutropenia was significantly lower in the treatment group compared to the control group (3.1% vs 35.3%, p = 0.005). No significant differences were observed in the rates of grade ≥ 3 thrombocytopenia (6.3% vs 17.6%, p = 0.326) and leukopenia (3.1% vs 0.0%, p = 1.000). Grade≥2 CIN was significantly lower in the treatment group (25.0% vs. 76.5%, p < 0.001). Conclusion: In GI cancer patients on oral agents, primary PEG-rhG-CSF prophylaxis was well-tolerated and reduced grade ≥2 CIN, though randomized studies are needed. Clinical Trial Registration: https://www.chictr.org.cn , identifier ChiCTR2100054854.
- 14 April 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1764358
Open AccessSafety and efficacy of PEG-rhG-CSF as primary prophylaxis for neutropenia in gastrointestinal cancer patients receiving combination chemotherapy including oral agents: a prospective, exploratory, non-randomized controlled study
Purpose: The safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for prevention of chemotherapy-induced neutropenia (CIN) in patients undergoing oral chemotherapy remain unclear. This study aimed to investigate the safety and efficacy of PEG-rhG-CSF as primary prophylaxis for CIN in gastrointestinal (GI) cancer patients receiving combination chemotherapy regimens that include oral chemotherapy agents. Methods: This is a prospective, single-center, open-label, exploratory, non-randomized controlled study. GI cancer patients was treated with intravenous oxaliplatin (130mg/m 2 on day 1) combined with either oral capecitabine (1000mg/m 2 ) or S−1 (an oral fluoropyrimidine combination of tegafur, gimeracil, and oteracil potassium; 40–60 mg) administered twice daily on days 1–14 of a 3−week cycle. The treatment group received subcutaneous injection of PEG-rhG-CSF (6mg) 24 hours after oxaliplatin, while the control group received no primary prophylaxis. The primary endpoint was safety, and secondary endpoints included the incidence of CIN. Results: Between March 2022 and January 2023, 49 patients were screened, and 43 patients who completed at least two treatment cycles were included in the final analysis (26 in treatment group and 17 in control group). The overall adverse events (AEs) did not differ statistically (93.8% vs 100.0%, p = 0.542). For grade ≥ 3 AEs, the incidence of neutropenia was significantly lower in the treatment group compared to the control group (3.1% vs 35.3%, p = 0.005). No significant differences were observed in the rates of grade ≥ 3 thrombocytopenia (6.3% vs 17.6%, p = 0.326) and leukopenia (3.1% vs 0.0%, p = 1.000). Grade≥2 CIN was significantly lower in the treatment group (25.0% vs. 76.5%, p < 0.001). Conclusion: In GI cancer patients on oral agents, primary PEG-rhG-CSF prophylaxis was well-tolerated and reduced grade ≥2 CIN, though randomized studies are needed. Clinical Trial Registration: https://www.chictr.org.cn , identifier ChiCTR2100054854.
- Open Access
- 22 January 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2610907
Development and validation of a predictive model for high-risk immune-related adverse events in gastric cancer patients treated with ICIs
Immune checkpoint inhibitors (ICIs) may cause immune-related adverse events (irAEs), ranging from mild to life-threatening. High-risk irAEs can lead to treatment discontinuation and higher mortality, though ICI-treated patients' death rate is under 5%. Currently, no reliable biomarkers predict irAEs' occurrence or severity. This study investigates the link between accessible biomarkers and high-risk irAEs in gastric cancer patients on ICIs, as well as to develop and assess a predictive model for such events. Data were collected from patients with gastric cancer who received ICIs therapy between May 2020 and March 2025. The incidence and risk factors associated with irAEs were analyzed using the chi-square test or the Mann-Whitney U test. Univariate and multivariate logistic regression analyses were conducted to develop a predictive model. This model was validated through 10-fold cross-validation and assessed using the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), calibration curves, and decision curve analysis. A total of 184 gastric cancer patients receiving ICIs therapy were enrolled in this study. The incidence of irAEs of any grade was 21.2%, while the incidence of grade ≥3 irAEs was 12.5%. Multivariate logistic regression analysis identified NLR-1 (p < .001), NLR2-1 (p < .001), PLR-1 (p = .001), tumor thickness (p = .018), CV (p = .001), and intratumoral necrosis (p = .028) as independent predictors of grade ≥3 irAEs. The AUC of the developed model was 0.878, with a sensitivity of 78.26%, specificity of 80.12%, PPV of approximately 80.95%, and NPV of approximately 75.52%. The corrected C-index, derived from bootstrap resampling, was 0.849, and both calibration curves and decision curve analysis confirmed good calibration and clinical utility. These predictors may aid risk stratification and optimized patient management.
- 22 January 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2610907
Open AccessDevelopment and validation of a predictive model for high-risk immune-related adverse events in gastric cancer patients treated with ICIs
Immune checkpoint inhibitors (ICIs) may cause immune-related adverse events (irAEs), ranging from mild to life-threatening. High-risk irAEs can lead to treatment discontinuation and higher mortality, though ICI-treated patients' death rate is under 5%. Currently, no reliable biomarkers predict irAEs' occurrence or severity. This study investigates the link between accessible biomarkers and high-risk irAEs in gastric cancer patients on ICIs, as well as to develop and assess a predictive model for such events. Data were collected from patients with gastric cancer who received ICIs therapy between May 2020 and March 2025. The incidence and risk factors associated with irAEs were analyzed using the chi-square test or the Mann-Whitney U test. Univariate and multivariate logistic regression analyses were conducted to develop a predictive model. This model was validated through 10-fold cross-validation and assessed using the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), calibration curves, and decision curve analysis. A total of 184 gastric cancer patients receiving ICIs therapy were enrolled in this study. The incidence of irAEs of any grade was 21.2%, while the incidence of grade ≥3 irAEs was 12.5%. Multivariate logistic regression analysis identified NLR-1 (p < .001), NLR2-1 (p < .001), PLR-1 (p = .001), tumor thickness (p = .018), CV (p = .001), and intratumoral necrosis (p = .028) as independent predictors of grade ≥3 irAEs. The AUC of the developed model was 0.878, with a sensitivity of 78.26%, specificity of 80.12%, PPV of approximately 80.95%, and NPV of approximately 75.52%. The corrected C-index, derived from bootstrap resampling, was 0.849, and both calibration curves and decision curve analysis confirmed good calibration and clinical utility. These predictors may aid risk stratification and optimized patient management.
- Open Access
- 2 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1848
A novel nomogram based on DLL3 and PD-L1 for predicting the prognosis of patients with small cell lung cancer
Background Small cell lung cancer (SCLC) is known for its highly invasive nature and low 5-year survival rate. Although immunotherapy has shown enhancements in survival among SCLC patients, there is a call for improved precision in targeting beneficiary populations. The development of the Delta-like ligand 3 (DLL3)-targeted drug Rovalpituzumab Tesirine (Rova-T) was halted due to insufficient efficacy, prompting a closer examination of factors influencing treatment effectiveness. This study aims to create a prognostic model for SCLC patients based on protein expression levels to enhance prognosis determination and guide clinical decision-making. cal or histopathological examination from March 13, 2017 to March 12, 2022 in Changzhi People's Hospital, Shanxi were enrolled. The study had specific criteria for
- 2 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1848
Open AccessA novel nomogram based on DLL3 and PD-L1 for predicting the prognosis of patients with small cell lung cancer
Background Small cell lung cancer (SCLC) is known for its highly invasive nature and low 5-year survival rate. Although immunotherapy has shown enhancements in survival among SCLC patients, there is a call for improved precision in targeting beneficiary populations. The development of the Delta-like ligand 3 (DLL3)-targeted drug Rovalpituzumab Tesirine (Rova-T) was halted due to insufficient efficacy, prompting a closer examination of factors influencing treatment effectiveness. This study aims to create a prognostic model for SCLC patients based on protein expression levels to enhance prognosis determination and guide clinical decision-making. cal or histopathological examination from March 13, 2017 to March 12, 2022 in Changzhi People's Hospital, Shanxi were enrolled. The study had specific criteria for
- Open Access
- 20 November 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1650111
Long-term survival after solitary ocular metastasis following radical resection of esophagogastric junction carcinoma: a rare case report
Background: Isolated ocular metastasis from esophagogastric junction (EGJ) cancer is extremely rare, and no standardized therapeutic approach has been established to date. Reporting such cases may help clarify optimal management strategies for uncommon metastatic patterns. Case presentation: We describe a 44-year-old male patient who developed isolated ocular oligometastasis 10 months after radical EGJ cancer resection. Comprehensive evaluation confirmed left eye involvement. Following multidisciplinary team (MDT) discussion, a combined treatment plan was implemented, starting with systemic therapy consisting of docetaxel, tegafur/gimeracil/oteracil (S-1), and tislelizumab. After achieving disease stabilization, the patient underwent left eye enucleation with ocular prosthesis implantation, followed by adjuvant radiotherapy and maintenance S-1 chemotherapy. At a 55-month follow-up, he remains disease-free with an excellent performance status (PS 0). Conclusion: This case highlights that integrated multimodal therapy—including systemic and local interventions—can result in long-term survival for patients with isolated ocular metastasis from EGJ cancer. MDT-based, individualized treatment planning is essential for optimizing outcomes in rare metastatic scenarios and may inform future precision oncology approaches.
- 20 November 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1650111
Open AccessLong-term survival after solitary ocular metastasis following radical resection of esophagogastric junction carcinoma: a rare case report
Background: Isolated ocular metastasis from esophagogastric junction (EGJ) cancer is extremely rare, and no standardized therapeutic approach has been established to date. Reporting such cases may help clarify optimal management strategies for uncommon metastatic patterns. Case presentation: We describe a 44-year-old male patient who developed isolated ocular oligometastasis 10 months after radical EGJ cancer resection. Comprehensive evaluation confirmed left eye involvement. Following multidisciplinary team (MDT) discussion, a combined treatment plan was implemented, starting with systemic therapy consisting of docetaxel, tegafur/gimeracil/oteracil (S-1), and tislelizumab. After achieving disease stabilization, the patient underwent left eye enucleation with ocular prosthesis implantation, followed by adjuvant radiotherapy and maintenance S-1 chemotherapy. At a 55-month follow-up, he remains disease-free with an excellent performance status (PS 0). Conclusion: This case highlights that integrated multimodal therapy—including systemic and local interventions—can result in long-term survival for patients with isolated ocular metastasis from EGJ cancer. MDT-based, individualized treatment planning is essential for optimizing outcomes in rare metastatic scenarios and may inform future precision oncology approaches.
- 23 September 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 230, 115808
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
- 23 September 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 230, 115808
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial